Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Li Auto Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.36 (market cap $5.85B), while Li Auto Inc trades at $11.36 (market cap $10.83B). The key difference: Li Auto Inc is the larger of the two by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Li Auto Inc for 101 Days on average.
| IOVA | LI | |
|---|---|---|
Market Cap | $5.85B | $10.83B |
Volume | 14,517,176 | 2,002,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $14.82 | $23.61 |
52-Week Low | $1.81 | $10.69 |
Typical Hold Time | 0 Days | 101 Days |
Enterprise Value | $5.78B | $258.87M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Li Auto (LI) trades at $10.90, near 52-week lows amid declining delivery volumes and negative earnings surprises. The stock shows bearish technical signals with oversold RSI levels, while fundamentals reveal revenue contraction from $144.5B (2024) to $112.3B (2025) and negative net margins. Recent vehicle launches (Li i9, MEGA) aim to counter competitive pressures in China's EV market, but cash flow trends show operational challenges with -$8.6B operating cash flow in 2025.
Outlook remains challenged by execution risks and market saturation, though analyst consensus target of $15.18 suggests 39% upside. Key risks include persistent cash burn, intense domestic competition, and macroeconomic headwinds. The valuation appears reasonable with P/S of 0.73, but profitability recovery is critical for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
